Abstract 1043: Efficacy and mechanistic insights of Shengyang Qushi Decoction in managing surufatinib-associated diarrhea
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-1043
Abstract: Surufatinib, a novel TKI targeting VEGFRs, FGFR1, and CSF1R, treats advanced neuroendocrine tumors but often causes diarrhea, which impairs patients’ health and anti-tumor efficacy. We’ve successfully established a rat model of surufatinib-induced diarrhea. This study… read more here.
Keywords: decoction; control; group; dose decoction ... See more keywords